Skip to main content

Global Downstream Processing Market to Surpass 83.47 Billion by 2030 Driven by Rising Demand for Biopharmaceuticals

SkyQuest projects that the global downstream processing market will attain a value of USD 83.47 billion by 2030, with a CAGR of 15.21% during the forecast period (2023-2030). The global downstream processing market demand for biopharmaceuticals is witnessing robust growth, driven by several key factors. One of the primary drivers is expanding bioprocessing capacity, which allows for the efficient production of biopharmaceuticals at larger scales to meet rising demand. Additionally, there is a growing acceptance of single-use technology in bioprocessing, which streamlines production processes and reduces contamination risks, further fueling the sector’s growth.

Westford USA, Feb. 05, 2024 (GLOBE NEWSWIRE) — According to SkyQuest, the growing popularity and rising demand for biopharmaceuticals, including vital products such as monoclonal antibodies, vaccines, and recombinant proteins, has consistently risen in the downstream processing market. Downstream processing is pivotal in this dynamic landscape, critical in purifying and isolating these intricate biological products. Its primary objective is to guarantee these therapeutics’ safety, quality, and efficacy.

Browse in-depth TOC on the “Downstream Processing Market”

  • Pages – 157
  • Tables – 67
  • Figures – 77

The relentless progress in biotechnology has ushered in an era of unprecedented innovation, resulting in the development of novel and intricate biopharmaceutical products in the global downstream processing market. In response to these advancements, downstream processing techniques and equipment have evolved significantly to address the unique challenges of processing these cutting-edge therapies.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/downstream-processing-market

Prominent Players in Global Downstream Processing Market

  • Thermo Fisher Scientific Inc.
  • GE Healthcare
  • Merck KGaA
  • Sartorius AG
  • Danaher Corporation
  • 3M Company
  • MilliporeSigma
  • Novasep Holding S.A.S.
  • Lonza Group Ltd.
  • Eppendorf AG
  • Repligen Corporation
  • Charles River Laboratories International, Inc.
  • Boehringer Ingelheim International GmbH
  • Avantor, Inc.
  • Corning Incorporated
  • Pall Corporation
  • Shimadzu Corporation
  • Agilent Technologies, Inc.
  • ABEC, Inc.
  • Nova Biomedical

Chromategraphy Segment to Dominate due to Widespread Adoption of Single-Use Chromatography

The downstream processing market saw the purification by chromatography segment taking the lead, contributing 40.98% of the total revenue in 2022. This dominance can be attributed to the widespread adoption of single-use chromatography and filtration systems, which have become industry standards for downstream bioprocessing.

The market in North America emerged as the dominant force in the downstream processing market, capturing the largest revenue share at 34.57% in 2022. This commanding position can be attributed to several key factors bolstering the region’s biopharmaceutical industry. North America benefits from substantial government support to promote and advance bioprocess technologies.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/downstream-processing-market

Filters Segment is Expected to Witness Significant Growth due to Rising Demand for Downstream Processing

Filters segment is projected to experience the highest CAGR of 16.10% within the downstream processing market between 2023 and 2030 This remarkable growth can be attributed to a pivotal factor driving the demand for downstream processing, namely the expanded utility of filters in viral inactivation.

Regional markets Asia Pacific is poised for remarkable growth in the downstream processing market, with an anticipated highest growth rate of 15.67% during the period spanning from 2023 to 2030. This remarkable expansion is primarily driven by the escalating investments made by both developers and consumers in biotechnology.

A comprehensive analysis of the major players in the downstream processing market has been recently conducted in this report. The report encompasses various aspects, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavours to develop innovative solutions to cater to the growing demand.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/downstream-processing-market

Key Developments in Downstream Processing Market

  • Thermo Fisher Scientific unveiled a groundbreaking downstream processing platform in 2023. This innovative platform is specifically designed to empower biopharmaceutical companies by enhancing the efficiency and productivity of their manufacturing processes. The launch of this advanced technology underscores the industry’s relentless pursuit of improved manufacturing capabilities and quality assurance.
  • In 2023, GE Healthcare made a strategic acquisition by adding Cytiva to its portfolio. Cytiva has established itself as a prominent provider of downstream processing technologies tailored for the biopharmaceutical sector.

Key Questions Answered in the Global Downstream Processing Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • List the top companies in the market and explain how they have achieved their positions of influence.

                             

  • In what ways do regional trends and patterns differ within the global market, and how these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Next Generation Sequencing Market

Global 3D Cell Culture Market

Global Synthetic Biology Market

Global Biopharmaceutical Analytical Testing Services Market

Global Influenza Diagnostics Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.